Concepedia

Real‐world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post‐marketing study

Takao Katoh, Kana Kuwamoto, Daisuke Kato, Kentarou Kuroishi

International Journal of Urology · 2016 · 18 citations · 20 references

DOI

Abstract

Mirabegron was well tolerated in real-world Japanese patients with overactive bladder and coexisting cardiovascular disease. No unexpected cardiovascular safety concerns were observed.

References

20

Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels.

Annals of Internal Medicine · 1974 · 1.5K citations

, , +18

Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction

Debra E. Irwin, Zoë Kopp, Barnabie Agatep et al. · British Journal of Urology · 2011 · 987 citations

Comparing Adherence and Persistence Across 6 Chronic Medication Classes

Jason Yeaw, Joshua S. Benner, John G. Walt et al. · Journal of Managed Care Pharmacy · 2009 · 547 citations · Full text

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Vik Khullar, G. Amarenco, J.C. Angulo et al. · European Urology · 2012 · 416 citations

, , +6

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

Victor W. Νitti, Stephen M. Auerbach, Nancy Martin et al. · The Journal of Urology · 2012 · 364 citations